Related Experiment Video
Updated: Feb 25, 2026

Application and Methodology of the Non-destructive 19F Time-domain NMR Technique to Measure the Content in Fluorine-containing Drug Products
Published on: August 22, 2017
Delafloxacin: First Global Approval
1Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Abstract:
Delafloxacin (Baxdela™) is a fluoroquinolone antibacterial with activity against both gram-positive and gram-negative pathogens being developed by Melinta Therapeutics. The drug is being investigated or considered as a treatment for various bacterial infections and in June 2017 received approval in the USA for the treatment of acute bacterial skin and skin structure infections. This article summarizes the milestones in the development of delafloxacin leading to this first global approval for the treatment of acute bacterial skin and skin structure infections.
Insights
Delafloxacin is a novel fluoroquinolone antibiotic approved for acute bacterial skin infections. This summary outlines its development milestones leading to this significant regulatory approval.
Area of Science:
- Pharmacology
- Infectious Diseases
- Drug Development
Background:
- Delafloxacin is a fluoroquinolone antibacterial agent.
- It exhibits activity against Gram-positive and Gram-negative pathogens.
- Melinta Therapeutics is developing delafloxacin for various bacterial infections.
Purpose of the Study:
- To summarize the development milestones of delafloxacin.
- To highlight the path to its first global approval.
Main Methods:
- Review of development history.
- Summary of key regulatory and clinical events.
Main Results:
- Delafloxacin received US FDA approval in June 2017.
- Approval was for the treatment of acute bacterial skin and skin structure infections.
Conclusions:
- Delafloxacin represents a new therapeutic option for bacterial skin infections.
- The drug's development journey culminated in a significant regulatory milestone.
More Related Videos
07:50Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
Published on: October 25, 2024
11:28A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically
Published on: September 9, 2015
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Antimicrobial Effectiveness
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Drugs for Treatment of Ulcerative Colitis in IBD
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Drug Regulation